EUCTR2017-003170-13-IT进行中（未招募）1 期
An open-label study to evaluate the long-term safety and efficacy of evinacumab in patients with homozygous familial hypercholesterolemia - na
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 116
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male and female patients =12 years of age with HoFH. Patients aged =
- •12 years old will be enrolled only in countries where permitted by the
- •Regulatory Agency and Institutional Review Board (IRB) or Ethics Committee (EC).
- •2. Diagnosis of functional HoFH by at least 1 of the following genetic or
- •clinical criteria:
- •a. Documented functional mutation or mutations in both LDLR alleles
- •Note: patients who have null receptor mutations on both LDLR alleles, ie,
- •double null, are eligible
- •b. Presence of homozygous or compound heterozygous mutations in Apo
- •Note: patients who are double heterozygous, ie, mutations on different
- •genes (eg, LDLR/PCSK9) and patients with homozygous LDLRAP1
- •mutations are eligible
- •c. Untreated TC >500 mg/dL (12.93 mmol/L) and TG <300 mg/dL (3.39
- •mmol/L) AND both parents with documented TC >250 mg/dL (6.47
- •mmol) OR cutaneous or tendinous xanthoma before the age of 10 years
- •3. For patients who have participated in a previous evinacumab or
- •alirocumab study: completion of the study in which they participated.
- •4. Willing and able to comply with clinic visits and study-related
- •procedures.
- •5. Provide signed informed consent.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 94
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Concomitant medications and procedures that have not been stable prior to the baseline visit 2. Any new condition or worsening of an existing condition, which in the opinion of the investigator would make the patient unsuitable for enrollment, or could interfere with the patient participating in or completing the study.
- •3. History of a MI, unstable angina leading to hospitalization, coronary artery bypass graft surgery, percutaneous coronary intervention, uncontrolled cardiac arrhythmia, carotid surgery or stenting, stroke, transient ischemic attack, valve replacement surgery, carotid revascularization, endovascular procedure or surgical intervention for peripheral vascular disease within 3 months prior to the baseline visit 4. Presence of any clinically significant uncontrolled endocrine disease known to influence serum lipids or lipoproteins 5. Newly diagnosed (within 3 months prior to screening visit diabetes mellitus or poorly controlled (HbA1c >9%) diabetes
- •6. Use of systemic corticosteroids, unless used as replacement therapy for pituitary/adrenal disease with a stable regimen for at least 6 weeks prior to screening visit
- •7. Use of estrogen or testosterone therapy unless the regimen has been stable 6 weeks prior to the screening visit and no plans to change the regimen during the study 8. Systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg at the screening visit 9. History of cancer within the past 5 years, except for adequately treated basal cell skin cancer, squamous cell skin cancer, or in situ cervical cancer 10. History of New York Heart Association (NYHA) Class IV heart failure within 12 months before screening 11. Laboratory findings during the screening period (applies to patients undergoing Screening): • Alanine aminotransferase or aspartate aminotransferase >3 x upper limit of normal (ULN)(1 repeat lab is allowed) • CPK >3 x ULN (1 repeat lab is allowed) • Positive serum beta-human chorionic gonadotropin or urine pregnancy test in WOCBP • TSH >1.5 x ULN of the central laboratory (1 repeat lab is allowed) for patients not on thyroid replacement therapy
- •Positive test for hepatitis B surface antigen and/or hepatitis C antibody (associated with a positive HCV RNA polymerase chain reaction) • eGFR <30 mL/min/1.73 m2 (calculated by central lab) • Postmenopausal status will be confirmed by measurement of folliclestimulating hormone (FSH) 12. Member of the clinical site study team and/or his/her immediate family. 13. Pregnant of breastfeeding women 14. Women of child bearing potential (see protocol for more information) 15. Men who are sexually active with WOCBP and are unwilling to
- •consistently use condoms during the study drug treatment period and for 24 weeks after the last injection of study drug, regardless of vasectomy status. Sperm donation is prohibited during the study and for up to 24 weeks after the last injection of study drug.
- •16. LDL-C level <40 mg/dL at screening visit 17. Use of any active investigational drugs (except alirocumab) within 1 month or 5 half lives prior to the screening visit, whichever is longer. 18. Age <12 years at the screening visit 19. Tanner stage <2 at the screening visit Exclusion Criteria for Patients from a Previous Evinacumab Study
研究者
相似试验
进行中（未招募）
1 期
ong-term, safety and tolerability study of AFQ056 in adolescent patients with Fragile X Syndrome (Open–label)Fragile X syndromeMedDRA version: 14.1 Level: PT Classification code 10017324 Term: Fragile X syndrome System Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2011-002379-40-GBovartis Pharma Services AG119
进行中（未招募）
1 期
ong-term, safety and tolerability study of AFQ056 in adolescent patients with Fragile X Syndrome (Open–label)Fragile X syndromeMedDRA version: 14.1Level: PTClassification code 10017324Term: Fragile X syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2011-002379-40-BEovartis Pharma Services AG180
进行中（未招募）
不适用
ong-term, Safety, Tolerability and Efficacy Study of AFQ056 in Adult Patients With Fragile X SyndromeFragile X SyndromeMedDRA version: 14.1Level: PTClassification code 10017324Term: Fragile X syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2011-001952-12-ITOVARTIS FARMA200
招募中
3 期
An open-label study to evaluate the long-term safety and efficacy of evinacumab in patients with homozygous familial hypercholesterolemiahomozygous familial hypercholesterolemiahereditary abnormal high cholesterol level1008362410013317NL-OMON55891Regeneron Pharmaceuticals, Inc.5
进行中（未招募）
1 期
ong-term, Safety, Tolerability and Efficacy Study of AFQ056 in Adult Patients With Fragile X SyndromeFragile X SyndromeMedDRA version: 16.1 Level: PT Classification code 10017324 Term: Fragile X syndrome System Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2011-001952-12-GBovartis Pharma Services AG148